Literature DB >> 23559219

Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study.

Mei Peng1, Keming Gao, Yiling Ding, Jianjun Ou, Joseph R Calabrese, Renrong Wu, Jingping Zhao.   

Abstract

OBJECTIVE: This study aims to investigate the developmental effects of atypical antipsychotics on infants who were born to mothers taking an atypical antipsychotic throughout pregnancy.
METHOD: The developmental progress of 76 infants who experienced fetal exposure to atypical antipsychotics was compared to that of 76 matched control infants who had no fetal exposure to any antipsychotics. Planned assessment included Apgar score, body weight, height, and the cognitive, language, motor, social-emotional, and adaptive behavior composite scores of the Bayley Scales of Infant and Toddler Development, third edition (BSID-III). Student's t test and Chi-square analysis were used as appropriate. Repeated measurements were evaluated by analysis of covariance.
RESULTS: At 2 months of age, the mean composite scores of cognitive, motor, social-emotional, and adaptive behavior of BSID-III were significantly lower in atypical antipsychotic-exposed infants than the controls. More atypical antipsychotic-exposed infants had delayed development in cognitive, motor, social-emotional, and adaptive behavior domains as defined by the composite score of <85 in these subscales of BSID-III. At 12 months of age, there were no significant differences between the two groups in all mean composite scores of BSID-III. More atypical antipsychotic-exposed infants had low birth weight than the controls (13.2 vs. 2.6 %, P = 0.031), although there were no significant difference in mean birth weight and height between the two groups.
CONCLUSION: Fetal exposure to atypical antipsychotics may cause short-term delayed development in cognitive, motor, social-emotional, and adaptive behavior, but not in language, body weight, or height.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23559219     DOI: 10.1007/s00213-013-3060-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  22 in total

1.  Measuring outcomes after extreme prematurity with the Bayley-III Scales of infant and toddler development: a cautionary tale from Australia.

Authors:  Michael E Msall
Journal:  Arch Pediatr Adolesc Med       Date:  2010-04

2.  Safety of clozapine in 2 successive pregnancies.

Authors:  Nitin Gupta; Sandeep Grover
Journal:  Can J Psychiatry       Date:  2004-12       Impact factor: 4.356

3.  Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation.

Authors:  D N Mendhekar
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

4.  Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.

Authors:  Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka
Journal:  J Clin Psychiatry       Date:  2009-06-02       Impact factor: 4.384

5.  The effects of novel antipsychotics on glucose and lipid levels.

Authors:  Donna A Wirshing; Jennifer A Boyd; Laura R Meng; Jacob S Ballon; Stephen R Marder; William C Wirshing
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

6.  Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.

Authors:  Patricia Gassó; Sergi Mas; Oriol Molina; Miquel Bernardo; Amalia Lafuente; Eduard Parellada
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-08-22       Impact factor: 5.067

7.  Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial.

Authors:  Maria Makrides; Robert A Gibson; Andrew J McPhee; Lisa Yelland; Julie Quinlivan; Philip Ryan
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

8.  Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.

Authors:  James J Newham; Simon H Thomas; Karine MacRitchie; Patricia R McElhatton; R Hamish McAllister-Williams
Journal:  Br J Psychiatry       Date:  2008-05       Impact factor: 9.319

9.  Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference?

Authors:  Herng-Ching Lin; I-Ju Chen; Yi-Hua Chen; Hsin-Chien Lee; Fang-Jen Wu
Journal:  Schizophr Res       Date:  2010-01       Impact factor: 4.939

10.  Clozapine use in two women with schizophrenia during pregnancy.

Authors:  Alaattin Duran; M Mufit Ugur; Senol Turan; Murat Emul
Journal:  J Psychopharmacol       Date:  2008-01       Impact factor: 4.153

View more
  16 in total

1.  One-Year Developmental Outcomes for Infants of Mothers With Bipolar Disorder.

Authors:  Aimee K Santucci; Lynn T Singer; Stephen R Wisniewski; James F Luther; Heather F Eng; Dorothy K Sit; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2017 Sep/Oct       Impact factor: 4.384

Review 2.  Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.

Authors:  Sabrina J Khan; Madeleine E Fersh; Carrie Ernst; Kim Klipstein; Elizabeth Streicker Albertini; Shari I Lusskin
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

3.  Use of Antipsychotic Drugs During Pregnancy.

Authors:  Hannah K Betcher; Catalina Montiel; Crystal T Clark
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-30

Review 4.  Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects.

Authors:  Megan Galbally; Martien Snellen; Josephine Power
Journal:  Ther Adv Drug Saf       Date:  2014-04

Review 5.  Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.

Authors:  Katharine Baratz Dalke; Amy Wenzel; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

Review 6.  Psychopharmacological Decision Making in Bipolar Disorder During Pregnancy and Lactation: A Case-by-Case Approach to Using Current Evidence.

Authors:  Elizabeth Albertini; Carrie L Ernst; Rachel S Tamaroff
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

Review 7.  The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review.

Authors:  Per Damkier; Poul Videbech
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

8.  Risk of Fetal Death after Treatment with Antipsychotic Medications during Pregnancy.

Authors:  Merete Juul Sørensen; Maiken Ina Siegismund Kjaersgaard; Henrik Søndergaard Pedersen; Mogens Vestergaard; Jacob Christensen; Jørn Olsen; Erik Parner; Lars Henning Pedersen; Bodil Hammer Bech
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

9.  Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis.

Authors:  Ping Shao; Jianjun Ou; Mei Peng; Jingping Zhao; Jindong Chen; Renrong Wu
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

Review 10.  [Antipsychotics during pregnancy: a systematic review].

Authors:  Thomas Hillemacher; Susanne Simen; Marie-Kathrin Rehme; Helge Frieling
Journal:  Nervenarzt       Date:  2020-09-30       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.